Ventricular septal defect cardiac catheterization: Difference between revisions
Jump to navigation
Jump to search
/* Recommendations for Cardiac Catheterization (DO NOT EDIT){{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 guidelines for the management of adults with congenital heart dis... |
No edit summary |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
{{CMG}}; '''Associate Editor-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu],[[Priyamvada Singh]], [[MBBS]] | {{CMG}}; '''Associate Editor-In-Chief:''' [[User:KeriShafer|Keri Shafer, M.D.]] [mailto:kshafer@bidmc.harvard.edu],[[Priyamvada Singh]], [[MBBS]] | ||
== Cardiac Catheterization == | == Cardiac Catheterization == | ||
===Criteria for Cardiac Catheterization=== | |||
1. The Mayo Clinic recommends cardiac catheterization for all adults and adolescents to quantify the degree of pulmonary vascular obstruction, except in those who clearly appear to have a small VSD. | 1. The Mayo Clinic recommends cardiac catheterization for all adults and adolescents to quantify the degree of pulmonary vascular obstruction, except in those who clearly appear to have a small VSD. | ||
| Line 29: | Line 27: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Cardiac catheterization]] can be useful for adults with VSD in whom noninvasive data are inconclusive and further information is needed for management. Data to be obtained include the following: | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Cardiac catheterization]] can be useful for adults with VSD in whom noninvasive data are inconclusive and further information is needed for management. Data to be obtained include the following:<nowiki>"</nowiki> | ||
'''a.''' Quantification of shunting. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''a.''' Quantification of shunting. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
'''b.''' Assessment of pulmonary pressure and resistance in patients with suspected [[PAH]]. Reversibility of PAH should be tested with various [[vasodilator]]s. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''b.''' Assessment of pulmonary pressure and resistance in patients with suspected [[PAH]]. Reversibility of PAH should be tested with various [[vasodilator]]s. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | |||
'''c.''' Evaluation of other lesions such as [[aortic regurgitation]] (AR) and double-chambered [[right ventricle]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''c.''' Evaluation of other lesions such as [[aortic regurgitation]] (AR) and double-chambered [[right ventricle]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | |||
'''d.''' Determination of whether multiple VSDs are present before surgery. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''d.''' Determination of whether multiple VSDs are present before surgery. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
'''e.''' Performance of [[coronary arteriography]] is indicated in patients at risk for [[coronary artery disease]] | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''e.''' Performance of [[coronary arteriography]] is indicated in patients at risk for [[coronary artery disease]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''f.''' VSD anatomy, especially if device closure is contemplated. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|} | |} | ||
| Line 50: | Line 53: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | | colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | ||
|- | |- | ||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Device closure of a muscular VSD may be considered, especially if the VSD is remote from the [[tricuspid valve]] and the [[aorta]], if the VSD is associated with severe left-sided heart chamber enlargement, or if there is [[PAH]].''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])<nowiki>"</nowiki> | | bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Device closure of a muscular VSD may be considered, especially if the VSD is remote from the [[tricuspid valve]] and the [[aorta]], if the VSD is associated with severe left-sided heart chamber enlargement, or if there is [[PAH]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
== References == | == References == | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Cardiology]] | |||
[[Category:Congenital heart disease]] | |||
[[Category:Pediatrics]] | |||
[[Category:Disease]] | |||
[[Category:Needs overview]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 18:01, 8 January 2013
|
Ventricular septal defect Microchapters | |
|
Differentiating Ventricular Septal Defect from other Diseases | |
|---|---|
|
Diagnosis | |
|
ACC/AHA Guidelines for Surgical and Catheter Intervention Follow-Up | |
|
Case Studies | |
|
Ventricular septal defect cardiac catheterization On the Web | |
|
American Roentgen Ray Society Images of Ventricular septal defect cardiac catheterization | |
|
Ventricular septal defect cardiac catheterization in the news | |
|
Risk calculators and risk factors for Ventricular septal defect cardiac catheterization | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Keri Shafer, M.D. [2],Priyamvada Singh, MBBS
Cardiac Catheterization
Criteria for Cardiac Catheterization
1. The Mayo Clinic recommends cardiac catheterization for all adults and adolescents to quantify the degree of pulmonary vascular obstruction, except in those who clearly appear to have a small VSD.
2. Infants suspected of having a large defect should undergo cardiac catheterization in the first year of life which should allow surgical correction prior to the onset of permanent pulmonary vascular obstructive disease.
2008 ACC/AHA Guidelines for the Management of Adults With Congenital Heart Disease (DO NOT EDIT)[1]
Recommendations for Cardiac Catheterization (DO NOT EDIT)[1]
| Class I |
| "1. Cardiac catheterization to assess the operability of adults with ventricular septal defect (VSD) and pulmonary arterial hypertension (PAH) should be performed in an adult congenital heart disease (ACHD) regional center in collaboration with experts. (Level of Evidence: C) " |
| Class IIa |
| "1. Cardiac catheterization can be useful for adults with VSD in whom noninvasive data are inconclusive and further information is needed for management. Data to be obtained include the following:" |
| "a. Quantification of shunting. (Level of Evidence: B)" |
| "b. Assessment of pulmonary pressure and resistance in patients with suspected PAH. Reversibility of PAH should be tested with various vasodilators. (Level of Evidence: B) " |
| "c. Evaluation of other lesions such as aortic regurgitation (AR) and double-chambered right ventricle. (Level of Evidence: C) " |
| "d. Determination of whether multiple VSDs are present before surgery. (Level of Evidence: C)" |
| "e. Performance of coronary arteriography is indicated in patients at risk for coronary artery disease. (Level of Evidence: C)" |
| "f. VSD anatomy, especially if device closure is contemplated. (Level of Evidence: C)" |
Recommendation for Interventional Catheterization (DO NOT EDIT) [1]
| Class IIb |
| "1. Device closure of a muscular VSD may be considered, especially if the VSD is remote from the tricuspid valve and the aorta, if the VSD is associated with severe left-sided heart chamber enlargement, or if there is PAH. (Level of Evidence: C)" |
References
- ↑ 1.0 1.1 1.2 Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.